Area A and the melanoma in situ instead harbored amplifications of RAF1 (encoding CRAF) as the likely MAP-kinase pathway driver (Fig. 4a–c), and this RAF1 amplification was absent from all other areas. Here, RAF1 is linked to melanoma.